Is SMMT or SPRO more undervalued in 2026?

CirclFi compares Summit Therapeutics Inc. (SMMT) and Spero Therapeutics, Inc. (SPRO) using 13 institutional-grade valuation models. SMMT has a Quality of Company score of 4.4/10 while SPRO scores 7.5/10.

Which is a better buy — SMMT or SPRO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SMMT and SPRO valuations compare?

SMMT at $17.41 and SPRO at $2.90 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SMMT vs SPRO Valuation Comparison 2026 — Intrinsic Value Analysis

SMMT

Biotechnology

Summit Therapeutics Inc.

Quality

4.4

out of 10

Value Trap

SAFE

Price

$17.41

Last close

Models

12/13

Active

SPRO

Biotechnology

Spero Therapeutics, Inc.

Quality

7.5

out of 10

Value Trap

WARN

Price

$2.90

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	SMMT Fair Value	SMMT Upside	SPRO Fair Value	SPRO Upside
Bayesian DCF	Intrinsic	$5.97	-65.7%	$1.28	-55.9%
Earnings Power Value	Intrinsic	$10.70	-51.5%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.86	-95.0%	$1.96	-32.3%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SMMT vs SPRO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SMMT vs SPRO — Which Stock Is More Undervalued?

SPRO scores higher with a 7.5/10 quality rating vs SMMT's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Summit Therapeutics Inc. (SMMT) and Spero Therapeutics, Inc. (SPRO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SMMT currently trades at $17.41 with a QOC of 4.4/10, while SPRO trades at $2.90 with a QOC of 7.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).